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A range of 7-oxo, 8-oxo and 9-oxo amino acids, analogues of 8-oxo-2-aminodecanoic acid, 
one of the key components of the cyclic tetrapeptide apicidin, has been prepared by a 
three-step process involving copper-catalysed allylation of serine-, aspartic acid- and 
glutamic acid-derived organozinc reagents, followed by cross-metathesis of the resulting 
terminal alkenes with unsaturated ketones, and hydrogenation.  The intermediate 7-oxo-5-
WﾐﾗﾐWゲ ┌ﾐSWヴ┘Wﾐデ ; ｴｷｪｴﾉ┞ Sｷ;ゲデWヴWﾗゲWﾉWIデｷ┗W ふSヴ дΓヶぎヴぶ ;IｷS-catalyzed aza-Michael reaction 
to give trans-2,5-disubstituted pyrrolidines, 5-substituted proline derivatives.  The aza-
Michael reaction was first observed when the starting enones were allowed to stand in 








The synthesis of 8-oxo-2-aminodecanoic acid (Aoda) 1, one of the key components of the 
cyclic tetrapeptide apicidin 2,
1-3
 has attracted considerable attention, as a result of the 
biological activity of apicidin,
4,5
 and closely related analogues.
6-10
  A number of approaches 
to the synthesis of Aoda 1 have been adopted, including the use of chiral pool starting 
materials,
9,11-14
 and the use of chiral auxiliary groups.
15-18
  Of most direct relevance to the 
topic of this paper is the report on the use of radical addition of chiral non-racemic amino 
acid fragments to enones.
12
  However, there is as yet no general approach to a range of 
simple analogues of 8-oxo-2-aminodecanoic acid in which the position of the ketone and the 
length of the side-chain can be straightforwardly varied. 
 
WW ｴ;┗W SW┗WﾉﾗヮWS ; SｷヴWIデ ;ヮヮヴﾗ;Iｴ デﾗ デｴW ゲ┞ﾐデｴWゲｷゲ ﾗa Wﾐ;ﾐデｷﾗﾏWヴｷI;ﾉﾉ┞ ヮ┌ヴW ü-amino 
acids using a family of organozinc reagents 6-8, each prepared from the corresponding alkyl 
iodide 3-5.
19
  Zinc reagents 6-8 can undergo Negishi cross-coupling with a variety of coupling 
partners.
19
  Copper-promoted reaction of zinc reagent 6 with a range of electrophiles, 
including allylic halides, is possible.
20
  Specifically copper-catalyzed reaction of zinc reagent 3 
with allyl chloride gave protected butenylglycine 9,
21
 and the protected pentenylglycine 10 
has also been prepared by related chemistry.
22
  We considered that extension of this 





There is significant literature precedent that amino acids incorporating a terminal alkene in 
the sidechain can undergo cross-metathesis reaction
23,24





 A recent paper describes application of this approach to 
cyclic tetrapetide derivatives.
29
  It therefore appeared entirely reasonable that the terminal 
alkenes 9-11 might undergo cross-metathesis with simple enones.  Subsequent 
hydrogenation would be expected to give the desired analogues of 8-oxo-2-aminodecanoic 
acid, in a straightforward and flexible manner. 
Results and Discussion 
Synthesis of the iodide 3 was carried out according to our previously reported methods 
from appropriately protected derivatives of serine.
30
 Iodides 4 and 5 were prepared from 
protected aspartic and glutamic acids by reduction via the mixed anhydride,
31
 an 
improvement on the method using N-hydroxysuccinimide activation,
32
 followed by standard 






Conversion of the iodide 3 into the corresponding zinc reagent 6 using iodine to activate the 
zinc metal prior to insertion, and copper catalysed allylation using allyl chloride, gave the 
expected product 9 in slightly higher yield (75%) than our previously reported method.
21
 
Others have successfully prepared 9 using this general approach.
33
  Conversion of each of 
the two iodides 4 and 5 into the corresponding zinc reagents using ultrasonication, followed 
by allylation using allyl chloride in the presence of CuBr.DMS (0.1 eq.), gave the 
corresponding allylated products in yields of 10 (64%) and 11 (38%), respectively (Scheme 
2).  While the yield of 10 is comparable to that obtained for 9, the yield of 11 was 
disappointing.  In the latter case, the mass balance was the protonated zinc reagent 12, and 
attempts to improve this yield, including omitting the use of sonication, were not successful. 
Scheme 2 
 
Cross-metathesis reactions of each of the terminal alkenes 9-11 using the Grubbs 2
nd
 
generation catalyst with a range of unsaturated ketones gave excellent yields of the 






Scheme 3. Cross-metathesis of terminal alkenes 
 
Table 1. Cross-metathesis of terminal alkenes 
 
Homodimers of 9-11 were detected in all the crude reaction mixtures by MS analysis. This 
observation was not unexpected, since terminal alkenes are known to undergo rapid 
homodimerization under similar conditions.
34,35
 When the alkene 10 was subjected to 
Grubbs 2
nd
 generation catalyst in the absence of enone, the homodimer 16 was isolated in 
excellent yield (98%). Subjection of 16 to the standard cross-metathesis conditions with 1-
hexen-3-one gave the expected product 14c (41%), together with recovered homodimer 16 





Enone equiv. Product Yield % 
9 1 Me CH3 3.0 13a 91 
9 1 Me C2H5 3.0 13b 92 
9 1 Me C3H7 2.5 13c 90 
10 2 Bn CH3 3.0 14a 89 
10 2 Bn C2H5 5.0 14b 90 
10 2 Bn C3H7 2.5 14c 86 
11 3 Me CH3 2.5 15a 82 
11 3 Me C2H5 2.5 15b 82 




conditions used for the initial cross-metathesis, we can conclude that it is probably not an 
intermediate in that process even though it is a substrate for the cross-metathesis reaction. 
Scheme 4 
 
Hydrogenation of each of the enones 13-15 was carried out under standard conditions, 
leading to the desired protected amino acids 17-19 (Scheme 5, Table 2).  In the case of the 
three benzyl esters 14a-c, the final isolated product was the corresponding free carboxylic 







Table 2. Hydrogenation of cross-metathesis products 
 
These results demonstrate that it is possible to prepare a range of simple analogues of 8-
oxo-2-aminodecanoic acid in which the position of the ketone and the length of the side-
chain can be straightforwardly varied, simply by choice of starting amino acid (serine, 
aspartic acid or glutamic acid), and enone. 
During the process of characterization of the enones 13a-c, and in particular upon allowing a 
solution of each of these enones to stand in CDCl3, they were each converted in high yield 
into the corresponding pyrrolidines 20-22, in an intramolecular aza-Michael reaction.  Use of 
purified CDCl3, in which any HCl present in the CDCl3 was removed by passage through UG1 
alumina, prevented the aza-Michael reaction from occurring, allowing characterization of 
the enones 13a-c.  In separate experiments, each of the enones 13a-c was separately 
treated with catalytic amounts of dry HCl in CH2Cl2 which resulted in efficient cyclization to 







 Yield % 
13a 1 Me CH3 17a Me 94 
13b 1 Me C2H5 17b Me 99 
13c 1 Me C3H7 17c Me 98 
14a 2 Bn CH3 18a H 90 
14b 2 Bn C2H5 18b H 89 
14c 2 Bn C3H7 18c H 98 
15a 3 Me CH3 19a Me 94 
15b 3 Me C2H5 19b Me 99 




that the aza-Michael reaction was acid catalysed, something that has been observed 
previously.
36-38
  What was striking about each of the three pyrrolidines 20-22 resulting from 
acid-catalyzed cyclization is that they appeared to be formed with very high 
diastereoselectivity, with dr values ranging from 96:4 to 98:2 (determined by GC analysis, 
and also corroborated by NMR in the case of 20a/20b).  X-ray diffraction analysis of the 
major product obtained by cyclisation of 13b provided a definitive answer, showing that the 
major isomer was of trans-configuration 21b. In order to exclude the possibility that we had 
inadvertently selected a crystal of the minor isomer, the 
1
H NMR of the specific crystal used 
for X-ray analysis was recorded. Although the concentration of the NMR sample was low, 
the spectrum matched closely that of the bulk material.  The 
1
H NMR spectra of the 
products formed from acid catalysed cyclisation of 13a and 13c were essentially identical to 
the 
1
H NMR spectrum of 21b (apart from the signals due to the different side-chains) which 
confirms that the products therefore have structures 20b and 22b, respectively. 
Scheme 6 
 
Table 3. Acid-Catalyzed Cyclization of Amino Enones 13 
Substrate R Product Conversion *d.r. (cis : trans)  
13a CH3 20a/b Complete  0.04 : 0.96
a,b
 














 ratio determined with GC. 
Boc deprotection of each of the compounds 20b, 21b, 22b using trifluoroacetic acid 
(Scheme 7) gave the corresponding trifluoroacetate salts 23, 24, and 25 in essentially 
quantitative yield. Each of the trifluoroacetate salts 23, 24, and 25 was determined to be of 
trans configuration by X-ray diffraction. Since the structure of 21b had already been 
established as the trans-pyrrolidine, this demonstrated that the deprotection reaction had 
proceeded without influencing the stereochemistry (for example by promoting a reversible 
aza-Michael process), which means that the assignments already made by comparison of 
the 
1
H NMR spectra of 20b and 22b with 21b are confirmed. 
Scheme 7 
 
A similar process has been reported previously, in which the cross-metathesis of Z-protected 
unsaturated amines with enones in the presence of a Lewis acid (BF3.Et2O) leads to 2,5-
disubstituted pyrrolidines with moderate levels of stereoselectivity (in the range 2:1 to 6:1 
in favor of the trans-isomer).
39
  Strong acid catalysis (TfOH) has also been used to promote 
the cyclization of a related Cbz-protected amino enone, again with a moderate levels of 
stereoselectivity (39:61 in favor of the trans-isomer).
38
  The high levels of 
diastereoselectivity in the formation of trans-2,5-disubstituted pyrrolidines that we have 




principal differences between our substrates and those previously reported are the nature 
of the nitrogen protecting group, and the presence of a carbomethoxy group.  In addition, 
the choice of acid catalyst may be important.  Further studies on the influence of these 
features appear to be warranted. 
Experimental Section 
HRMS measuments were carried out using Electrospray ionisation, with a TOF mass 
analyzer.  IR spectra were recorded as thin films.  Compound 3 was prepared by the 
literature method.
30
  The preparation of compound 4 was carried out by the literature 
method,
31
 but on a substantially larger scale than that reported.  In our hands, 4 was 
isolated as a yellow crystalline solid (mp 55-56 °C), as we had previously reported (mp 54-55 
°C),
32
 rather than as an oil.
31
  All other data for 4 matched that reported.
31,32
  Compound 5 
(the methyl ester)
40
 was prepared by the general method reported for the synthesis of the 
corresponding benzyl ester.
31
  GC analysis of compounds 20 に 22 was carried out using a 
Phenomenex ZB-5 column (0.25 mm i.d. × 30 m., film thickness =250 µm.), oven 
temperature = 145 
o
C isothermal; carrier gas: H2 at 1.4 mL/min.; injection: 250 
o
C/split = 
34.7:1; detection: FID at 300 
o
C. 
General Procedure A: Allylation reactions 
A two-necked round bottomed flask was charged with a magnetic stirrer bar was fitted with 
a rubber septum and three-way tap. The flask was flame-dried under vacuum and backfilled 
with nitrogen three times. Zinc dust (see each procedure for amount) was added, flame-
dried and again evacuated and backfilled with nitrogen three times, with continuous 
stirring. The flask was allowed to cool, dry DMF (1 mL/1 mmol of alkyl iodide) was added via 




amount) was added by rapid removal and replacement of the three-way tap under a stream 
of nitrogen. The mixture was stirred for 1-2 minutes, until the solution was colorless. The 
alkyl iodide (1.0 mmol) was added by rapid removal and replacement of the three-way tap 
under a stream of nitrogen (in the case of compound 5, the alkyl iodide was dissolved in 
DMF and added by syringe). The mixture was stirred and an exotherm was observed stirring 
continued for a further 50 minutes at r.t. or 35-40 minutes at 35 
o
C with sonication; these 
details are specified with each example. The solid zinc dust was then allowed to settle, 
giving a clear supernatant. During the activation period, a separate two-necked round 
bottomed flask fitted with a magnetic stirrer bar, rubber septum and three-way tap was 
flame-dried under vacuum and backfilled with nitrogen three times. The flask was allowed 
to cool, CuBr.DMS (0.1 eq. relative to alkyl iodide) was added and gently heated then 
evacuated and backfilled with nitrogen until the CuBr.DMS changed appearance from a 
grey-brown to light green powder. The flask was allowed to cool, before adding dry DMF 
(0.6 mL/1 mmol of alkyl iodide) and allyl chloride (see each procedure for amount) dropwise 
via syringe. The mixture was stirred at room temperature for about 5 minutes, at which 
point the supernatant from the solution containing the organozinc reagent was added 
dropwise via syringe, and the reaction mixture was stirred at room temperature for 3 h. The 
crude reaction mixture was directly applied to SiO2 column, using a gradient of 20-30% 
EtOAc in petroleum ether. 
Methyl (2S)-2-([(tert-butoxy)carbonyl]amino)hex-5-enoate (9) 
General procedure A using zinc dust (1.95 g, 30 mmol, 2.5 eq.), iodine (0.6 g, 2.4 mmol, 0.2 
eq.), 3 (3.94 g, 12 mmol, 1 eq.), CuBr.DMS (0.246 g, 1.2 mmol, 0.1 eq.), and allyl chloride 




enoate 9 (2.2 g, 9 mmol, 75 %) as a colorless oil. Zinc insertion took 50 minutes at r.t. ぷüへD -
17.0 (c 1.0, MeOH), lit.
33ぎ ぷüへD -20.7 ( c 0.97, MeOH); Rf = 0.57 (20% EtOAc in petroleum 
ether); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヵくΒヰ ふヱ Hが SSデが J = 16.9, 10.3 and 6.6 Hz), 4.98-5.08 
(3 H, m), 4.28-4.37 (1 H, m), 3.74 (3 H, s), 2.06-2.17 (2 H, m), 1.85-1.96 (1 H, m), 1.65-1.77 (1 
H, m), 1.44 (9 H, s); 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヱΑンくンが ヱヵヵくンが ヱンヶくΓが ヱヱヵくΑ, 79.8, 52.9, 
52.3, 31.9, 29.5, 28.3; IR (cm
-1
), 3370, 1742, 1712, 1516, 1451, 1365, 1254, 1168; m/z (ES+) 
found MH
+




General procedure A using zinc dust (1.17 g, 18 mmol, 3 eq.), iodine (0.335 g, 1.32 mmol, 
0.22 eq.), 4 (2.5 g, 6 mmol, 1 eq.), CuBr.DMS (0.123 g, 0.6 mmol, 0.1 eq.), and allyl chloride 
(0.7 mL, 8.4 mmol, 1.4 eq.). Zinc insertion took 35 minutes with sonication at 35 
o
C. 
Purification by column chromatography (20% EtOAc in petroleum ether) followed by 
preparative HPLC (XBridge Prep OBD C18 5µm 19 mm id x 250 mm, using 30:70 
water/acetonitrile, at a flow rate of 17 mL.min
-1 
and UV detection at 210 nm) gave benzyl 
(2S)-2-([(tert-butoxy)carbonyl]amino)hept-6-enoate 10 (1.28 g, 3.8 mmol, 64% ) as a 
colorless oil (tR = 8-ヱヰ ﾏｷﾐぶく ぷüへD -4.0 (c 1, CHCl3) lit.22ぎ ぷüへD -5.5 ( c 1.4, CH2Cl2), Rf = 0.5 (20% 
EtOAc in petroleum ether). 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ Αくンヱ-7.40 (5 H, m), 5.72 (1 H, 
ddt, J = 16.9, 10.3 and 6.7 Hz), 5.22 (1 H, d, J = 12.4 Hz), 5.13 (1 H, d, J = 12.4 Hz), 5.05 (1 H, 
d, J = 8.3 Hz), 5.02-4.92 (2 H, m), 4.30-4.39 (1 H, m), 1.96-2.12 (2 H, m), 1.75-1.88 (1 H, m), 
1.58-1.69 (1 H, m), 1.31-1.52 (11 H, m). 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヱΑヲくΑが ヱヵヵくヴが 
137.9, 135.5, 128.6, 128.4, 128.2, 115.1, 79.8, 66.9, 53.4, 33.1, 32.1, 28.3, 24.4; IR (cm
-1
), 
3368, 1745, 1712, 1634, 1501, 1366, 1253, 1165, 1001, 912; m/z (ES+) found MH
+
: 334.2028, 







General procedure A using zinc dust (487.5 mg, 7.5 mmol, 2.5 eq.), iodine (152.3 mg, 0.6 
mmol, 0.2 eq.), 5 (1.10 g, 3 mmol, 1 eq.), CuBr.DMS (61.5 mg, 0.3 mmol, 0.1 eq.), and allyl 
chloride (320 µl, 3.9 mmol, 1.3 eq.) gave methyl (2S)-2-([(tert-butoxy)carbonyl]amino)oct-7-
enoate 11 (311 mg, 1.15 mmol, 38%) as a colorless oil. Zinc insertion took 40 minutes with 
sonication at 35 
o
C. ぷüへD -17.6 (c 1.25, MeOH); Rf = 0.52 (20% EtOAc in petroleum ether); 1H 
NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヵくΑΑ ふヱ Hが SSデが J = 16.9, 10.1 and 6.8 Hz), 4.9-5.05 (3 H, m), 
4.25-4.33 (1 H, m), 3.73 (3 H, s), 1.99-2.1 (2 H, m), 1.69-1.86 (1 H, m), 1.53-1.68 (1 H, m), 
1.24-1.51 (4 H, m), 1.44 (9 H, s); 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヱΑンくヴが ヱヵヵくンが ヱンΒくヵが 
114.6, 79.8, 53.3, 52.2, 33.4, 32.6, 28.4, 28.3, 24.6; IR (cm
-1
), 3370, 1745, 1720, 1509, 1168; 
m/z (ES+) found MH
+
: 272.1850, C14H26NO4 requires 272.1862. 
General procedure B: Cross metathesis of unsaturated amino acids 
A two-necked round bottomed flask with a magnetic stirrer bar was fitted with a condenser 
equipped with a three-way tap on top and rubber septum. The flask was flame-dried under 
vacuum and backfilled with nitrogen three times. The flask was allowed to cool, before the 
unsaturated amino acid 9-11 and enone in dry degassed CH2Cl2 (2 mL) were added via 
syringe. Grubbs 2
nd
 generation catalyst (5 mol% relative to substrate) in dry CH2Cl2 (1 mL) 
was added by syringe, and the reaction mixture was heated at reflux for 7 h, allowed to cool 
to room temperature and concentrated. The residue was purified by column 
chromatography using a gradient of 15-35% EtOAc in petroleum ether.  




General procedure B using 9 (97 mg, 0.4 mmol, 1 eq.), 3-buten-2-one (100 µl, 1.2 mmol, 3 
eq.) and Grubbs 2
nd
 generation catalyst (16 mg, 0.02 mmol, 5 mol%) in CH2Cl2 (3 mL) gave 
methyl (2S, 5E)-2-([(tert-butoxy)carbonyl]amino)-7-oxooct-5-enoate 13a (104 mg, 0.36 
mmol, 91%) as an oil. ぷüへD +40.0 (c 0.4, CHCl3); Rf = 0.13 (20% EtOAc in petroleum ether); 1H 
NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヶくΑΑ ふヱ Hが Sデが J = 16.0 and 6.7 Hz), 6.09 (1 H, br.d, J = 16.0 Hz), 
5.08 (1 H, d, J = 8.1 Hz), 4.30-4.42 (1H, m), 3.76 (3 H, s), 2.19に2.39 (2 H, m), 2.25 (3 H, s), 
1.92-2.11 (1 H, m), 1.74-1.86 (1 H, m), 1.45 (9 H, s); 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヱΓΒくンが 
172.7, 155.3, 146.1, 131.9, 80.1, 52.8, 52.4, 31.3, 28.3, 28.2, 26.9; IR (cm
-1
), 3359, 1749, 
1715, 1673, 1518, 1450, 1371, 1253, 1166; m/z (ES+) found MH
+
: 286.1648, C14H24NO5 
requires 286.1654. 
Methyl (2S, 5E)-2-([(tert-butoxy)carbonyl]amino)-7-oxonon-5-enoate (13b) 
General procedure B using 9 (97 mg, 0.4 mmol, 1 eq.), 1-penten-3-one (120 µl, 1.2 mmol, 3 
eq.) and Grubbs 2
nd
 generation catalyst (16 mg, 0.02 mmol, 5 mol%) in CH2Cl2 (3 mL) gave 
methyl (2S, 5E)-2-([(tert-butoxy)carbonyl]amino)-7-oxonon-5-enoate 13b (110 mg, 0.37 
mmol, 92%) as an oil. ぷüへD +36.4 (c 0.55, CHCl3); Rf = 0.17 (20% EtOAc in petroleum ether); 1H 
NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヶくΑヶ ふヱ Hが Sデが J = 15.8 and 6.8 Hz), 6.09 (1 H, d, J = 15.8 Hz), 
5.13 (1 H, d, J = 7.6 Hz), 4.25-4.36 (1 H, m), 3.72 (3 H, s), 2.53 (2 H, q, J = 7.3 Hz), 2.17に2.35 (2 
H, m), 1.88-2.06 (1 H, m), 1.71-1.82 (1 H, m), 1.41 (9 H, s), 1.06 (3 H, t, J = 7.3 Hz); 
13
C NMR 
(100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヰヰくΑが ヱΑヲくΒが ヱヵヵくンが ヱヴヴくヶが ヱンヰくΑが Βヰくヰが ヵヲくΓが ヵヲくヴが ンンくヴが ンヱくンが ヲΒくンが 
28.2, 8.0; IR (cm
-1
), 3346, 1747, 1708, 1669, 1512, 1448, 1363, 1167; m/z (ES+) found MH
+
: 
300.1800, C15H26NO5 requires 300.1811. 




General procedure B using 9 (97 mg, 0.4 mmol, 1 eq.), 1-hexen-3-one (117 µl, 1 mmol, 2.5 
eq.) and Grubbs 2
nd
 generation catalyst (16 mg, 0.02 mmol, 5 mmol%) in CH2Cl2 (3 mL) gave 
methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-oxodec-5-enoate 13c (113 mg, 0.36 
mmol, 90%) as an oil. ぷüへD +30.7 (c 0.88, CHCl3); Rf  = 0.17 (20% EtOAc in petroleum ether); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヶくΑΒ ふヱ Hが Sデが J = 15.8 and 6.8 Hz), 6.11 (1 H, d, J = 15.8 Hz), 
5.08 (1 H, d, J =7.6 Hz), 4.27-4.39 (1 H, m), 3.75 (3 H, s), 2.5 (2 H, t, J = 7.3 Hz),  2.19に2.37 (2 
H, m), 1.91-2.08 (1 H, m), 1.69-1.85 (1 H, m), 1.63 (2 H, sext., J = 7.4 Hz), 1.44 (9 H, s), 0.93 (3 
H, t, J = 7.5 Hz);
 13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヰヰくヴが ヱΑヲくΒが ヱヵヵくンが ヱヴヴくΑが ヱンヰくΓが Βヰくヱが 
52.9, 52.4, 42.2, 31.3, 28.3, 28.2, 17.6, 13.8; IR (cm
-1
), 3359, 1750, 1714, 1675, 1521, 1448, 
1366, 1249, 1167; m/z (ES+) found MH
+
: 314.1972, C16H28NO5 requires 314.1967. 
Benzyl (2S,6E)-2-([(tert-butoxy)carbonyl]amino)-8-oxonon-6-enoate (14a) 
General procedure B using 10 (133.4 mg, 0.4 mmol, 1 eq.), 3-buten-2-one (100 µl, 1.2 mmol, 
3 eq.) and Grubbs 2
nd
 generation catalyst (16 mg, 0.02 mmol, 5 mol%) in  CH2Cl2 (3 mL) gave 
benzyl (2S,6E)-2-([(tert-butoxy)carbonyl]amino)-8-oxonon-6-enoate 14a (134 mg, 0.36 
mmol, 89%) as an oil. ぷüへD -22.0 (c 0.91, MeOH); Rf = 0.32 (30% EtOAc in petroleum ether); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ Αくンヲ-7.42 (5 H, m), 6.70 (1 H, dt, J = 16.0 and 6.9 Hz), 6.04 
(1 H, d, J = 16.0 Hz), 5.22 (1 H, d, J = 12.2 Hz), 5.14 (1 H, d, J = 12.2, Hz), 5.05 (1 H, d, J = 8.1 
Hz), 4.33-4.41 (1 H, m), 2.13-2.31 (5 H, m), 1.77-1.91 (1 H, m), 1.59-1.72 (1 H, m), 1.37-1.57 
(2 H, m), 1.44 (9 H, s); 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヱΓΒくヵが ヱΑヲくヵが ヱヵヵくヴが 147.1, 135.3, 
131.6, 128.6, 128.5, 128.3, 79.9, 67.1, 53.2, 32.3, 31.7, 28.3, 26.9, 23.7; IR (cm
-1
), 3342, 
1715, 1694, 1673, 1625, 1499, 1364, 1250, 1157; m/z (ES+) found MH
+
: 376.2109, C21H30NO5 
requires 376.2124. 




General procedure B using 10 (134 mg, 0.4 mmol, 1 eq.), 1-penten-3-one (200 µl, 2 mmol, 5 
eq.) and Grubbs 2
nd
 generation catalyst (16 mg, 0.02 mmol, 5 mol%) in CH2Cl2 (3 mL) gave 
benzyl (2S,6E)-2-([(tert-butoxy)carbonyl]amino)-8-oxodec-6-enoate 14b (141 mg, 0.36 
mmol, 90%) as an oil. ぷüへD -19.5 (c 0.77, MeOH); Rf = 0.18 in ( 15% EtOAc in petroleum 
ether); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ Αくンヰ-7.39 (5 H, m), 6.72 (1 H, dt, J = 16.0 and 6.8  
Hz), 6.05 (1 H, br.d, J = 16.0 Hz), 5.21 (1 H, d, J = 12.2 Hz), 5.13 (1 H, d, J = 12.2 Hz), 5.08 (1 H, 
d, J = 8.3 Hz), 4.30-4.40 (1 H, m), 2.52 (2 H, q, J = 7.3 Hz), 2.11-2.27 (2 H, m), 1.77-1.89 (1 H, 
m), 1.58-1.71 (1 H, m), 1.36-1.56 (11 H, m), 1.10 (3 H, t, J = 7.3 Hz); 
13
C NMR (100 MHz, 
CDCl3ぶ ~ ppm: 200.8, 172.4, 155.4, 145.6, 135.3, 130.4, 128.6, 128.4, 128.3, 79.8, 67.1, 53.2, 
33.3, 32.2, 31.7, 28.3, 23.7, 8.1; IR (cm
-1
), 3362, 1741, 1696, 1673, 1629, 1499, 1248, 1159; 
m/z (ES+) found MH
+
: 390.2283, C22H32NO5 requires 390.2280. 
Benzyl (2S,6E)-2-([(tert-butoxy)carbonyl]amino)-8-oxoundec-6-enoate (14c) 
General procedure B using 10 (133.4 mg, 0.4 mmol, 1 eq.), 1-hexen-3-one (117 µl, 1 mmol, 
2.5 eq.) and Grubbs 2
nd
 generation catalyst (16 mg, 0.02 mmol, 5 mol%) in CH2Cl2 gave 
benzyl (2S,6E)-2-([(tert-butoxy)carbonyl]amino)-8-oxoundec-6-enoate 14c (140 mg, 0.35 
mmol, 86%) as an oil. ぷüへD -30.0 (c 0.1, MeOH); Rf = 0.22 (15% EtOAc in petroleum ether); 1H 
NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ Αくンン-7.41 (5 H, m), 6.73 (1 H, dt, J = 16.0 and 6.8 Hz), 6.06 (1 
H, br.d, J = 16.0), 5.22 (1 H, d, J = 12.2 Hz), 5.14 (1 H, d, J = 12.2 Hz), 5.04 (1 H, br.d, J = 8.3 
Hz), 4.32-4.42 (1 H, m,), 2.48 (2 H, t, J = 7.3 Hz), 2.13-2.27 (2 H, m), 1.78-1.91 (1 H, m), 1.57-
1.71 (3 H, m), 1.37-1.56 (11 H, m), 0.93 (3 H, t, J = 7.5 Hz); 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ 
200.6, 172.5, 155.5, 145.7, 135.3, 130.7, 128.6, 128.5, 128.3, 80.2, 67.1, 53.2, 42.1, 32.3, 
31.7, 28.3, 23.7, 17.6, 13.8; IR (cm
-1
), 3357, 1747, 1712, 1675, 1629, 1499, 1457, 1365, 1256, 
1162; m/z (ES+) found MH
+




Methyl (2S,7E)-2-([(tert-butoxy)carbonyl]amino)-9-oxodec-7-enoate (15a) 
General procedure B using 11 (108.5 mg, 0.4 mmol, 1 eq.), 3-buten-2-one (85 µl, 1 mmol, 
2.5 eq.) and Grubbs 2
nd
 generation catalyst (16 mg, 0.02 mmol, 5 mol%) in CH2Cl2 (3 mL) 
gave methyl (2S,7E)-2-([(tert-butoxy)carbonyl]amino)-9-oxodec-7-enoate 15a (103 mg, 0.33 
mmol, 82%) as an oil. ぷüへD +20.0 (c 0.95, CHCl3); Rf = 0.25 (30% EtOAc in petroleum ether); 1H 
NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヶくΑヶ ふヱ Hが Sデが J = 16.0 and 6.9 Hz), 6.05 (1 H, d, J = 16.0 Hz), 
5.04 (1H, br.d, J = 8.1 Hz), 4.24-4.34 (1 H, m), 3.73 (3 H, s), 2.17-2.26 (2 H, m), 2.23 (3 H, s), 
1.75-1.87 (1 H, m), 1.56-1.68 (1 H, m), 1.29-1.55 (4 H, m), 1.43 (9 H, s); 
13
C NMR (100 MHz, 
CDCl3ぶ ~ ヮヮﾏぎ ヱΓΒくヶが ヱΑンくヲが ヱヵヵくンが ヱヴΑくΑが ヱンヱくヵが ΑΓくΓが ヵンくヲが ヵヲくンが ンヲくヵが ンヲくヱが ヲΒくンが ヲΑくヶが ヲヶくΓが 
24.8; IR (cm
-1
), 3356, 1749, 1717, 1674, 1523, 1441, 1369, 1258, 1164; m/z (ES+) found MH
+
: 
314.1956, C16H28NO5 requires 314.1967. 
Methyl (2S, 7E)-2-([(tert-butoxy)carbonyl]amino)-9-oxoundec-7-enoate (15b) 
General procedure B using 11 (108.5 mg, 0.4 mmol, 1 eq.), 1-penten-3-one (100 µl, 1 mmol, 
2.5 eq.) and Grubbs 2
nd
 generation catalyst (16 mg, 0.02 mmol, 5 mol %) in CH2Cl2 (3 mL) 
gave methyl (2S,7E)-2-([(tert-butoxy)carbonyl]amino)-9-oxoundec-7-enoate 15b (108 mg, 
0.33 mmol, 82%) as an oil. ぷüへD +23.7 (c 0.93, CHCl3); Rf = 0.22 (20% EtOAc in petroleum 
ether); 
1
H NMR (500 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヶくΑΓ ふヱ Hが Sデが J = 16.0 and 6.9 Hz), 6.08 (1 H, br.d, J 
= 16.0 Hz), 5.02 (1 H, br.d, J = 7.5 Hz), 4.25-4.34 (1 H, m), 3.74 (3 H, s), 2.55 (2 H, q, J = 7.3 
Hz), 2.21 (2 H, dq, J = 1.3 and 7.2 Hz), 1.73-1.87 (1 H, m), 1.58-1.68 (1 H, m), 1.28-1.55 (4 H, 
m), 1.44 (9 H, s), 1.09 (3 H, t, J =7.3 Hz); 
13
C NMR (125 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヰヱくヰが ヱΑンくヲが 
155.3, 146.2, 130.2, 79.9, 53.2, 52.2, 33.2, 32.5, 32.1, 28.3, 27.6, 24.8, 8.1; IR (cm
-1
), 3357, 
1746, 1715, 1634, 1674, 1514, 1460, 1167; m/z (ES+) found MH
+





Methyl (2S,7E)-2-([(tert-butoxy)carbonyl]amino)-9-oxododec-7-enoate (15c) 
General procedure B using 11 (108.5 mg, 0.4 mmol, 1 eq.), 1-hexen-3-one (117 µl, 1 mmol, 
2.5 eq.) and Grubbs 2
nd
 generation catalyst (16 mg, 0.02 mmol, 5 mol%) in CH2Cl2 (3 mL) 
gave methyl (2S,7E)-2-([(tert-butoxy)carbonyl]amino)-9-oxododec-7-enoate 15c (125.4 mg, 
0.37 mmol, 91%) as an oil. ぷüへD +13.2 (c 0.38, CHCl3); Rf = 0.29 (20% EtOAc in petroleum 
ether); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヶくΑΑ ふヱ Hが Sデが J = 16.0 and 6.9 Hz), 6.07 (1 H, br.d, J 
= 16.0 Hz), 5.04 (1 H, br. d, J = 8.3 Hz), 4.24-4.32 (1 H, m), 3.72 (3 H, s), 2.49 (2 H, t, J = 7.3 
Hz), 2.19 (2 H, dq, J = 7.2 and 1.3 Hz), 1.74-1.85 (1 H, m), 1.56-1.67 (3 H, m), 1.27-1.54 (4 H, 
m), 1.42 (9 H, s), 0.92 (3 H, t, J = 7.5 Hz);
 13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヰヰくΑが ヱΑンくンが 
155.3, 146.4, 130.5, 79.9, 53.2, 52.2, 42.1, 32.5, 32.1, 28.3, 27.6, 24.8, 17.7, 13.8; IR (cm
-1
), 
3357, 1750, 1718, 1671, 1516, 1437, 1369, 1247, 1167; m/z (ES+) found MH
+
: 342.2269, 
C18H32NO5 requires 342.2280. 
1,12-Dibenzyl (2S,6E/Z,11S)-2,11-bis(([(tert-butoxy) carbonyl] amino))dodec-6-enedioate 
(16) 
General procedure B, using benzyl (2S)-2-([(tert-butoxy)carbonyl]amino)hept-6-enoate 10 
(110 mg, 0.33 mmol, 1 eq.) as the starting material and Grubbs 2
nd
 generation catalyst (14 
mg, 0.016 mmol, 5 mmol%), gave compound 16 (104 mg, 0.163 mmol, 98%) as an oil [üへD -
1.3 (c 1.5, CHCl3); Rf = 0.3 (20% EtOAc in petroleum ether); 
1
H NMR (400 MHz,CDCl3) ~ ヮヮﾏぎ 
7.29-7.40 (10 H, m), 5.25-5.36 (2 H, m), 5.21 (2 H, d, J = 12.5 Hz), 5.12 (2 H, d, J = 12.5 Hz), 
4.99-5.01 (2 H, m), 4.27-4.43 (2 H, m), 1.87-2.08 (4 H, m), 1.72-1.86 (2 H, m), 1.54-1.71 (2 H, 
m), 1.19-1.52 (4 H, m), 1.44 (18 H, s); 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヱΑヲくΒが ヱヵヵくヴが ヱンヵくヵが 
130.1, 128.6, 128.4, 128.3, 79.8, 66.9, 53.5, 32.5, 31.9, 28.3, 25.0; IR (cm
-1




1717, 1501, 1459, 1250, 1163; m/z (ES+) found MH
+
: 639.3638, C36H51N2O8 requires 
639.3645. 
General Procedure C: Hydrogenation of cross-metathesis product 
A two-necked round bottomed flask with magnetic stirrer bar was fitted with a rubber 
septum and three-way tap, and was flame-dried under vacuum and back-filled with nitrogen 
three times. The flask was allowed to cool, and palladium on carbon (10% w/w) (amount 
specified in each experiment) was added to the flask which was evacuated and back-filled 
with nitrogen three times. Then nitrogen gas line was replaced with balloon of hydrogen 
gas, and the cross-metathesis product (1 eq.) was added to the flask as a solution in EtOAc 
(7 mL) via syringe. The flask was evacuated until the reaction mixture began to boil, and 
then back-filled with hydrogen gas. This procedure was repeated three more times, and the 
reaction stirred at room temperature for 1 day. To remove the catalyst the mixture was 
filtered through Celite® and then washed with EtOAc. The filtrate and washings were 
combined, and the solvent was removed under reduced pressure. 
Methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-7-oxooctanoate (17a) 
General procedure C using 13a (105 mg, 0.368 mmol, 1 eq.) and 10% w/w palladium on 
carbon (20 mg) gave methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-7-oxooctanoate 17a (100 
mg, 0.348 mmol, 94%) as a colorless oil. ぷüへD +15.8 (c 0.95, CHCl3); Rf = 0.31 (40% EtOAc in 
petroleum ether); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヵくヰヲ ふヱ Hが Sが J = 8.1 Hz), 4.23-4.34 (1 H, 
m), 3.74 (3 H, s), 2.43 (2 H, t, J = 7.2 Hz), 2.13 (3 H, s), 1.73-1.87 (1 H, m), 1.52-1.68 (3 H, m), 
1.44 (9 H, s), 1.22-1.40 (2 H, m); 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヰΒくヶが ヱΑンくンが 155.4, 79.8, 
53.3, 52.3, 43.3, 32.5, 29.8, 28.3, 24.8, 23.2; IR (cm
-1
), 3370, 1749, 1715, 1516, 1439, 1364, 
1250, 1169; m/z (ES+) found MNa
+




Methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-7-oxononanoate (17b) 
General procedure C using 13b (58 mg, 0.194 mmol, 1 eq.) and 10% w/w palladium on 
carbon (10 mg) gave methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-7-oxononanoate 17b (58 
mg, 0.193 mmol, 99%) as a colorless oil. ぷüへD +16.0 (c 1, CHCl3); Rf = 0.22 (20% EtOAc in 
petroleum ether); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヵくヰン ふヱ Hが Sが J = 8.1 Hz), 4.21-4.31 (1 H, 
m), 3.70 (3 H, s), 2.34-2.43 (4 H, m), 1.69-1.84 (1 H, m), 1.50-1.66 (3 H, m), 1.42 (9 H, s), 
1.22-1.37 (2 H, m), 1.02 (3 H, t, J = 7.3 Hz); 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヱヱくンが ヱΑンくンが 
155.4, 79.8, 53.3, 52.2, 41.9, 35.9, 32.6, 28.3, 24.9, 23.3, 7.8; IR (cm
-1
), 3360, 1751, 1712, 
1519, 1455, 1370, 1256, 1167; m/z (ES+) found: MH
+ 
302.1955, C15H28NO5 requires 
302.1967. 
Methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-7-oxodecanoate (17c) 
General procedure C using 13c (89 mg, 0.284 mmol, 1 eq.) and 10% w/w palladium on 
carbon (40 mg) gave methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-7-oxodecanoate 17c (88 
mg, 0.279 mmol, 98%) as colorless oil. ぷüへD +15.0 (c 2, CHCl3); Rf = 0.46 (30% EtOAc in 
petroleum ether); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヵくヰヱ ふヱ Hが Sが J = 8.1 Hz), 4.23-4.34 (1 H, 
m), 3.73 (3 H, s), 2.39 (2 H, t, J = 7.3 Hz), 2.36 (2 H, t, J = 7.3 Hz), 1.71-1.87 (1 H, m), 1.51-1.67 
(5 H, m), 1.44 (9 H, s), 1.24-1.39 (2 H, m), 0.91 (3 H, t, J = 7.3 Hz); 
13
C NMR (100 MHz, CDCl3) 
~ ヮヮﾏぎ ヲヱヰくΒが ヱΑンくンが ヱヵヵくヴが ΑΓくΒが ヵンくンが ヵヲくヲが ヴヴくΑが ヴヲくンが 32.6, 28.3, 24.9, 23.3, 17.3, 13.7; IR 
(cm
-1
), 3370, 1749, 1715, 1514, 1454, 1367, 1250, 1170; m/z (ES+) found MH
+
: 316.2134, 




General procedure C using 14a (50 mg, 0.133 mmol, 1 eq.) and 10% w/w palladium on 




0.12 mmol 90%) as a colorless oil. ぷüへD +5.0 (c 1.0, CHCl3); Rf = 0.17 (EtOAc : petroleum ether 
: acetic acid, 5 : 5 : 0.1 mL); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヵくヰヲ ふヱ Hが Sが J = 7.8 Hz), 4.25-
4.35 (1 H, m), 2.44 (2 H, t, J = 7.3 Hz), 2.14 (3 H, s), 1.79-1.93 (1 H, m), 1.63-1.74 (1 H, m), 
1.58 (2 H, quint., J = 7.5 Hz), 1.27-1.48 (4 H, m), 1.45 (9 H, s); 
13
C NMR (100 MHz, CDCl3ぶ ~ 
ppm: 209.6, 176.9, 155.6, 80.1, 53.3, 43.5, 32.3, 29.8, 28.6, 28.3, 25.0, 23.4. IR (cm
-1
), 3340, 
1730, 1700, 1658, 1520, 1390, 1368, 1252, 1167; m/z (ES+) found MH
+
: 288.1806, C14H26NO5 
requires 288.1811. In the 
1
H NMR the carboxylic acid proton was not observed due, 




General procedure C using 14b (52 mg, 0.134 mmol, 1 eq.) and 10% w/w palladium on 
carbon (23 mg) gave (2S)-2-([(tert-butoxy)carbonyl]amino)-8-oxodecanoic acid 18b (35 mg, 
0.12 mmol, 89%) as a colorless oil. ぷüへD -37.2 (c 0.94, CHCl3); Rf = 0.28 (EtOAc : petroleum 
ether : acetic acid, 5 : 5 : 0.1 mL); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヵくヰヲ ふヱ Hが Sが J = 8.0 Hz), 
4.24-4.35 (1 H, m), 2.42 (2 H, q, J = 7.3 Hz), 2.41 (2 H, t, J = 7.3 Hz), 1.79-1.92 (1 H, m), 1.63-
1.74 (1 H, m), 1.58 (2 H, quint., J = 7.3 Hz), 1.27-1.48 (4 H, m), 1.45 (9 H, s), 1.05 (3 H, t, J = 
7.3 Hz); 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヱヲくヱが ヱΑヶくΓが ヱヵヵくヶが Βヰくヲが ヵンくンが ヴヲくヱが ンヵくΓが ンヲくヲが 
28.7, 28.3, 25.1, 23.5, 7.8; IR (cm
-1
), 3322, 1735, 1713, 1681, 1510, 1460, 1395, 1249, 1166; 
m/z (ES+) found MH
+
: 302.1953, C15H28NO5 requires 302.1967. 
(2S)-2-([(tert-Butoxy)carbonyl]amino)-8-oxoundecanoic acid (18c) 
General procedure C using 14c (82 mg, 0.2 mmol, 1 eq.) and 10% w/w palladium on carbon 
(37 mg) gave (2S)-2-([(tert-butoxy)carbonyl]amino)-8-oxoundecanoic acid 18c (62 mg, 0.196 
mmol, 98%) as a colorless oil. ぷüへD -16.0 (c 0.5, CHCl3); Rf = 0.25 (EtOAc : petroleum ether : 
acetic acid, 5 : 5 : 0.1 mL); 
1




4.35 (1 H, m), 2.40 (2 H, t, J = 7.8 Hz), 2.38 (2 H, t, J = 7.5 Hz), 1.77-1.93 (1 H, m), 1.52-1.74 (5 
H, m), 1.24-1.51 (4 H, m), 1.45 (9 H, s), 0.91 (3 H, t, J = 7.4 Hz); 
13
C NMR (100 MHz, CDCl3ぶ ~ 
ppm: 211.6, 176.9, 155.6, 80.2, 53.3, 44.7, 42.5, 32.2, 28.7, 28.3, 25.1, 23.4, 17.3, 13.7; IR 
(cm
-1
), 3346, 1717, 1701, 1688, 1511, 1453, 1366, 1243, 1159; m/z (ES+) found MH
+
: 
316.2119, C16H30NO5 requires 316.2124. In the 
1
H NMR the carboxylic acid proton was not 
observed due, presumably, to its broadness. 
Methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-9-oxodecanoate (19a) 
General procedure C using 15a (50 mg, 0.159 mmol, 1 eq.) and 10% w/w palladium on 
carbon (25 mg) gave methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-9-oxodecanoate 19a 
(47.5 mg, 0.15 mmol, 94%) as a colorless oil. ぷüへD +10.9 (c 1.1, CHCl3); Rf = 0.17 (20% EtOAc in 
petroleum ether); 
1
H NMR (500 MHz, CDCl3ぶ ~ ヮヮﾏぎ 4.99 (1 H, br.d, J = 7.7 Hz), 4.22-4.32 (1 
H, m), 3.72 (3 H, s), 2.39 (2 H, t, J = 7.4 Hz), 2.12 (3 H, s), 1.69-1.82 (1 H, m), 1.51-1.65 (3 H, 
m), 1.43 (9 H, s), 1.22-1.37 (6 H, m); 
13
C NMR (125 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヰΓくヱが 173.4, 155.3, 
79.8, 53.3, 52.1, 43.6, 32.6, 29.8, 28.9, 28.8, 28.3, 25.0, 23.6; IR (cm
-1
), 3365, 1745, 1712, 
1516, 1438, 1370, 1249, 1164; m/z (ES+) found MH
+
: 316.2137, C16H30NO5 requires 
316.2124. In the 
1
H NMR the carboxylic acid proton was not observed due, presumably, to 
its broadness. 
Methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-9-oxoundecanoate (19b) 
General procedure C using 15b (49 mg, 0.15 mmol, 1 eq.) and 10% w/w palladium on carbon 
(17 mg) gave methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-9-oxoundecanoate 19b (49 mg, 
0.148 mmol, 99%) as a colorless oil. ぷüへD +19.3 (c 0.68, CHCl3); Rf = 0.27 (20% EtOAc in 
petroleum ether); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏ: 5.00 (1 H, br.d, J = 8.1 Hz), 4.22-4.31 (1 




H, s), 1.20-1.37 (6 H, m), 1.03 (3 H, t, J = 7.3 Hz); 
13
C NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヱヱくΑが 
173.4, 155.3, 79.8, 53.3, 52.2, 42.2, 35.8, 32.7, 28.9 (2 C), 28.3, 25.1, 23.7, 7.8; IR (cm
-1
), 
3367, 1746, 1711, 1704, 1518, 1455, 1364, 1168; m/z (ES+) found MH
+
: 330.2290, C17H32NO5 
requires 330.2280. 
Methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-9-oxododecanoate (19c) 
General procedure C using 15c (44 mg, 0.129 mmol, 1 eq.) and 10% w/w palladium on 
carbon (17 mg) gave methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-9-oxododecanoate 19c 
(44 mg, 0.128 mmol, 99%) as a colorless oil. ぷüへD +14.1 (c 0.85, CHCl3); Rf = 0.57 (30% EtOAc 
in petroleum ether); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏ: 5.00 (1 H, br.d, J = 8.3 Hz), 4.23-4.33 
(1 H, m), 3.73 (3 H, s), 2.37 (2 H, t, J = 7.3 Hz), 2.36 (2 H, t, J = 7.3 Hz), 1.69-1.85 (1 H, m), 
1.49-1.67 (5 H, m), 1.44 (9 H, s), 1.21-1.37 (6 H, m), 0.90 (3 H, t, J = 7.5 Hz); 
13
C NMR (100 
MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヱヱくヴが ヱΑンくヴが ヱヵヵくヴが ΑΓくΒが ヵンくヴが ヵヲくヲが ヴヴくΑが ヴヲくΑが ンヲくΑが ヲΒくΓ ふヲ Cぶが ヲΒくンが 
25.1, 23.6, 17.3, 13.7; IR (cm
-1
), 3370, 1749, 1713, 1692, 1520, 1462, 1247, 1172; m/z (ES+) 
found MH
+
: 344.2437, C18H34NO5 requires 344.2437. 
General Procedure D: Intramolecular aza-Michael reactions 
The cross-metathesis product 13 (1 eq.) was dissolved in CH2Cl2 (2 mL) and a solution of HCl 
in Et2O (1 M, 0.6 mol%) was added. After 19 h stirring the resulting solution was 
concentrated under reduced pressure to give the product. 
1-tert-Butyl 2-methyl (2S,5R)-5-(2-oxopropyl)pyrrolidine-1,2-dicarboxylate (20a) & 1-tert-
butyl 2-methyl (2S,5S)-5-(2-oxopropyl)pyrrolidine-1,2-dicarboxylate (20b)  
General procedure D using methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-oxooct-5-
enoate 13a (32 mg, 0.112 mmol, 1 eq.) and 1 M HCl/Et2O (6.6 × 10
-4




mol%) in CH2Cl2 (2 mL), after 19 h stirring at r.t. gave the title compounds 20a/b (32 mg, 
0.11 mmol, 100%), as an oil, in a ratio of (0.04 cis 20a, tr 11.82 min: 0.96 trans 20b, tr 11.67 
min) based on GC and 
1
H NMR. ぷüへD -54.0 (c 1, CHCl3); Rf = 0.19 (20% EtOAc in petroleum 
ether);
 1
H NMR (500 MHz, DMSO 100 
o
Cぶ ~ ヮヮﾏぎ ヴくヱヴ-4.23 (2 H, m), 3.65 (3 H, s), 2.85 (1 H, 
br.d, J = 16.2 Hz), 2.53 (1 H, dd, J = 16.2 and 9.7 Hz), 2.17-2.29 (1 H, m), 2.09 (3 H, s), 1.95-
2.06 (1 H, m), 1.78-1.85 (1 H, m), 1.55-1.64 (1 H, m), 1.36 (9 H, s); 
13
C NMR (125 MHz, 
DMSOぶ ~ ヮヮﾏぎ ヲヰΑくヵ ふヲヰΑくヴぶが ヱΑンくヵ ふヱΑンくヰぶが ヱヵンくヱ ふヱヵンくヴぶが ΑΓくヵ ふΑΓくΒぶが ヵΓくヴ ふヵΓくヱぶが ヵヴくヱ 
(53.9), 52.3 (52.2), 47.2 (48.1), 30.6 (30.7), 28.6 (29.3), 28.3 (28.4), 27.9 (27.1); IR (cm
-1
), 
1752, 1703, 1396, 1210, 1165, 1126; m/z (ES+) found MH
+
: 286.1661, C14H24NO5 requires 
286.1654. In the 
13
C NMR the signals due to the minor rotamer are in parentheses. 
 
1-tert-Butyl 2-methyl (2S,5R)-5-(2-oxobutyl)pyrrolidine-1,2-dicarboxylate (21a) & 1-tert-
butyl 2-methyl (2S,5S)-5-(2-oxobutyl)pyrrolidine-1,2-dicarboxylate (21b) 
General procedure D using methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-oxonon-5-
enoate 13b (30 mg, 0.1 mmol, 1 eq.) and 1 M HCl/Et2O (6 × 10
-4 
mmol, 0.6 µL, 0.6 mol%) in 
CH2Cl2 (2 mL), after 19 h stirring at r.t. gave the title compounds 21a/b (30 mg, 100%) as a 
solid, in a ratio of (0.02 cis , tr 17.69 min: 0.98 trans, , tr 17.40 min) based on GC of the crude 
product, mp 52-54 
o
C; ぷüへD -50.5 (c 0.46, CHCl3); Rf = 0.22 (20% EtOAc in petroleum ether); 1H 
NMR (500 MHz, DMSO 100 
o
Cぶ ~ ヮヮﾏぎ ヴくヲヲ-4.16 (2 H, m), 3.65 (3 H, s), 2.84 (1 H, br.dd, J = 
16.0 and 3 Hz), 2.52 (1 H, dd, J = 16.0 and 9.2 Hz), 2.41 (2 H, q, J = 7.4 Hz), 2.19-2.31 (1 H, m), 
1.96-2.08 (1 H, m), 1.78-1.85 (1 H, m), 1.55-1.63 (1 H, m), 1.36 (9 H, s), 0.96 (3 H, t, J = 7.3); 
13
C NMR (125 MHz, DMSOぶ ~ ヮヮﾏぎ ヲヰΓくΓ ふヲヰΓくΒぶが ヱΑンくヵ ふヱΑンくヰぶが ヱヵンくヱ ふヱヵ3.4), 79.5 (79.7), 




(27.1), 7.94 (7.98); IR (cm
-1
), 1745, 1705, 1396, 1366, 1212, 1175, 1123; m/z (ES+) found 
MH
+
: 300.1818, C15H26NO5 requires 300.1811. In the 
13
C NMR signals due to the minor 
rotamer are in parentheses. 
1-tert-Butyl 2-methyl (2S,5R)-5-(2-oxopentyl)pyrrolidine-1,2-dicarboxylate (22a) & 1-tert-
Butyl 2-methyl (2S,5S)-5-(2-oxopentyl)pyrrolidine-1,2-dicarboxylate (22b) 
General procedure D using methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-oxodec-5-
enoate 13c (49 mg, 0.16 mmol, 1 eq.) and 1 M HCl/Et2O (9 × 10
-4
 mmol, 0.9 µL, 0.6 mol%) in 
CH2Cl2 (2 mL), after 19 h stirring at r.t. gave the title compounds 22a/b (49 mg, 0.16 mmol, 
100%), as an oil, in a ratio of (0.02 cis, tr 25.62 min: 0.98 trans, tr 25.14 min) based on GC of 
the crude product; ぷüへD -56.0 (c 1.25, CHCl3); Rf = 0.18 (15% EtOAc in petroleum ether); 1H 
NMR (500 MHz, DMSO 100 
o
Cぶ ~ ヮヮﾏぎ ヴくヱヵ-4.22 (2 H, m), 3.65 (3 H, s), 2.84 (1 H, br.d, J = 
16.1 Hz), 2.52 (1 H, dd, J = 16.1 and 9.5 Hz), 2.38 (2 H, t, J = 7.3 Hz), 2.19-2.30 (1 H, m), 1.96-
2.07 (1 H, m), 1.78-1.86 (1 H, m), 1.56-1.64 (1 H, m), 1.52 (2 H, sextet, J = 7.3 Hz), 1.36 (9 H, 
s), 0.87 (3 H, t, J =7.4 Hz); 
13
C NMR (125 MHz, DMSOぶ ~ ヮヮﾏぎ ヲヰΓくヱ ふヲヰΓくヰぶが ヱΑンくヰ ふヱΑヲくヶぶが 
152.6 (152.9), 79.1 (79.3), 58.9 (58.7), 53.7 (53.5), 51.8 (51.7), 45.8 (46.6), 44.2 (44.3), 28.2 
(28.8), 27.8 (27.9), 27.5 (26.6), 16.5 (16.6), 13.5 (13.4); IR (cm
-1
), 1751, 1699, 1392, 1258, 
1085, 1020, 795; m/z (ES+) found MH
+
: 314.1982, C16H28NO5 requires 314.1967. In the 
13
C 
NMR signals due to the minor rotamer are in parentheses. 
General procedure E: Boc deprotection of pyrrolidines 20b, 21b and 22b 
The N-Boc protected compound was dissolved in CH2Cl2 (4 mL). Neat TFA (50 eq.) relative to 
the substrate was added and the reaction followed by TLC until the starting material has 




the TFA salts.  The salts were not sufficiently thermally stable for melting points to be 
determined. 
(2S,5S)-2-(Methoxycarbonyl)-5-(2-oxopropyl)pyrrolidin-1-ium trifluoroacetate (23) 
General procedure E using 20b (88 mg, 0.31 mmol, 1 eq.) and TFA (1.2 mL, 15.5 mmol, 50 
eq.) gave (2S, 5S)-2-(methoxycarbonyl)-5-(2-oxopropyl)pyrrolidin-1-ium trifluoroacetate 23 
(94 mg, 0.31 mmol, 100%) as a solid, mp decomp.; ぷüへD -10.0 (c 1, CHCl3); Rf = 0.075 (20% 
CHCl3, 30% petroleum ether and 50% acetonitrile), 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヴくヴΒ-
4.75 (1 H, m), 3.94-4.08 (1 H, m), 3.86 (3 H, s), 3.18-3.37 (1 H, m), 2.93-3.13 (1 H, m), 2.53-
2.67 (1 H, m), 2.19-2.36 (1 H, m), 2.22 (3 H, s), 2.04-2.18 (1 H, m), 1.85-2.00 (1 H, m); 
13
C 
NMR (100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヰヶくΒが ヱヶΓくΑが ヵΒくΒが ヵΑくヱが ヵンくΑが ヴヴくヱが ヲΓくΒが ヲΓくヵが ヲΑくΒき IR (cm-1), 
3425, 1751, 1715, 1676, 1445, 1366, 1245, 1185; m/z (ES+) found M
+
: 186.1125, C9H16NO3 
requires 186.1130.  In the 
1
H NMR there are additional signals in the low field range due to 
the two acidic NH protons, and trace residual CF3CO2H.  The chemical shifts are very variable 
depending on conditions. 
(2S,5S)-2-(Methoxycarbonyl)-5-(2-oxobutyl)pyrrolidin-1-ium trifluoroacetate (24) 
General procedure E using 21b (43 mg, 0.144 mmol, 1 eq.) and TFA (0.55 mL, 7.2 mmol, 50 
eq.) gave (2S,5S)-2-(methoxycarbonyl)-5-(2-oxobutyl)pyrrolidin-1-ium trifluoroacetate 24 
(45 mg, 0.143 mmol, 99% yield) as a solid, mp decomp.; ぷüへD -6.1 (c 1.15, CHCl3); Rf = 0.125 
(20% CHCl3, 30% petroleum ether and 50% acetonitrile); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ 
4.55-4.80 (1 H, m), 3.92-4.04 (1 H, m), 3.88 (3 H, s), 3.22-3.38 (1 H, m), 2.93-3.08 (1 H, m), 
2.60-2.72 (1 H, m), 2.41-2.59 (2 H, m), 2.21-2.35 (1 H, m), 2.05-2.18 (1 H, m), 1.91-2.05 (1 H, 
m), 1.08 (3 H, t, J = 7.1 Hz); 
13




43.1, 35.7, 30.1, 27.9, 7.3; IR (cm
-1
), 1752, 1715, 1674, 1446, 1246, 1203, 1176; m/z (ES+) 
found M
+
: 200.1293, C10H18NO3 requires 200.1287.  In the 
1
H NMR there are additional 
signals in the low field range due to the two acidic NH protons, and trace residual CF3CO2H.  
The chemical shifts are very variable depending on conditions. 
(2S,5S)-2-(Methoxycarbonyl)-5-(2-oxopentyl)pyrrolidin-1-ium trifluoroacetate (25) 
General procedure E using 22b (98 mg, 0.313 mmol, 1 eq.) and TFA (1.2 mL, 15.6 mmol, 50 
eq.) gave (2S, 5S)-2-(methoxycarbonyl)-5-(2-oxopentyl) pyrrolidin-1-ium trifluoroacetate 25 
(100 mg, 0.31 mmol, 99% yield) as a solid, mp decomp.; ぷüへD -2.0 (c 1, CHCl3); Rf = 0.15 (20% 
CHCl3, 30% petroleum ether and 50% acetonitrile); 
1
H NMR (400 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヴくヶヲ ふヱ 
H, t, J = 7.8 Hz), 3.89-4.04 (1 H, m), 3.87 (3 H, s), 3.29 (1 H, dd, J = 18.7 and 9.1 Hz), 2.97 (1 H, 
dd, J = 18.7 and 3.8 Hz), 2.56-2.67 (1 H, m), 2.35-2.55 (2 H, m), 2.20-2.34 (1 H, m), 2.03-2.16 
(1 H, m), 1.87-2.02 (1 H, m), 1.62 (2 H, sextet, J = 7.3 Hz), 0.92 (3 H, t, J = 7.3 Hz); 
13
C NMR 
(100 MHz, CDCl3ぶ ~ ヮヮﾏぎ ヲヰΒくΓが ヱヶΓくΑが ヵΒくΒが ヵΑくヲが 53.8, 44.4, 43.2, 29.9, 27.8, 16.8, 13.4; IR 
(cm
-1
), 1749, 1715, 1674, 1446, 1246, 1203, 1176; m/z (ES+) found M
+
: 214.1439, C11H20NO3 
requires 214.1443. In the 
1
H NMR there are additional signals in the low field range due to 
the two acidic NH protons, and trace residual CF3CO2H.  The chemical shifts are very variable 
depending on conditions. 
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